Compare LUNR & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LUNR | TARS |
|---|---|---|
| Founded | 2013 | 2016 |
| Country | United States | United States |
| Employees | 525 | N/A |
| Industry | Industrial Machinery/Components | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.7B |
| IPO Year | N/A | 2020 |
| Metric | LUNR | TARS |
|---|---|---|
| Price | $13.31 | $60.12 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 6 |
| Target Price | $22.35 | ★ $89.00 |
| AVG Volume (30 Days) | ★ 8.4M | 1.3M |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 48.21 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $451,360,000.00 |
| Revenue This Year | $343.00 | $56.43 |
| Revenue Next Year | $16.81 | $30.19 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 146.71 |
| 52 Week Low | $7.78 | $38.51 |
| 52 Week High | $46.75 | $85.25 |
| Indicator | LUNR | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 28.33 | 49.15 |
| Support Level | $12.70 | $56.05 |
| Resistance Level | $22.25 | $67.14 |
| Average True Range (ATR) | 1.00 | 3.38 |
| MACD | 0.23 | -0.11 |
| Stochastic Oscillator | 7.69 | 37.27 |
Intuitive Machines Inc is a space infrastructure and services company focused on enabling sustained human activity beyond Earth. It designs, builds, integrates, and operates space systems, offering infrastructure-as-a-service across low Earth orbit, geostationary orbit, cislunar space, and deep space. Its capabilities include spacecraft development and space-based network connectivity, serving commercial, civil, and national security customers. The company conducts sales both directly and through an extensive customer and partner network spanning North America, South America, Europe, Asia, and Australia, including rideshare delivery providers, lunar surface mobility providers, payload providers, communication satellite providers, and ground segment providers.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.